Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

Phase 1

• Conditions: Cerebral Ischemia; Myocardial Infarction; Thrombosis; Venous Thrombosis; Pulmonary Embolism

• Registration Number: NCT03001544
• Lead Sponsor: Translational Sciences, Inc.

Brief Summary

This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.

Detailed Description

This is a first-in-human, Phase 1 study of the safety, pharmacokinetics and pharmacodynamics of TS23 in healthy male volunteers.TS23 is a monoclonal antibody that inactivates alpha 2-antiplasmin. Four dose cohorts of six subjects will be studied in a single ascending dose trial at one clinical center.

Study Timeline

• Study Start: 2015-07
• Primary Completion: 2016-06
• Study First Submitted: 2016-11-11
• Status Verified: 2016-12
• Study First Submitted QC: 2016-12-20
• Last Update Submitted: 2016-12-20
• Study First Posted: 2016-12-23
• Last Update Posted: 2016-12-23
• Study Completion: 2017-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

• Able to provide written informed consent
• Healthy males age 18 years to 60 years of age
• Body mass index ≥ 20 and ≤ 33 kg/m squared

Exclusion Criteria

• Known allergies or hypersensitivities to blood products or derivatives or therapeutic proteins or product excipients or components of CHO cells
• Current alcohol or drug abuse or history of alcohol or drug abuse
• Participation in any trial with an investigational drug within 90 days prior to dosing
• Blood donation of more than 500 mL of blood within 90 days prior to dosing
• Any history of a bleeding or thrombotic disorder
• Any history of significant cardiac, pulmonary, renal, hepatic, neurologic, or immunologic disorder
• Over-the-counter medications, dietary supplements and herbal products (except a daily vitamin) within 14 days of drug administration or during the study
• No prescription medication for at least 14 days or 5-half-lives, whichever is longer, prior to study drug administration.
• Use of anticoagulants, fibrinolytic agents or non-steroidal anti-inflammatory medicines (except aspirin doses of 82 mg per day or less) for 2 weeks prior to and during the study
• Known hereditary fructosemia (due to sorbitol in the formulation)
• Any previous or current monoclonal antibody therapy
• History of trauma or surgery within the past 60 days or planned surgery within 30 days
• Abnormal baseline laboratory values or any laboratory values deemed clinically significant by the Investigator
• Recent history of head trauma in last 30 days prior to receiving TS23
• Unwillingness or inability to avoid contact sports or other activities with more than a small risk of head or facial trauma within 30 days of receiving TS23
• History of or risk of falls (e.g., due to dementia, frailty, etc.)
• Sexually active subjects must agree to use a reliable method of birth control (abstinence, condoms, vasectomy) and to not donate sperm for 3 months after receiving TS23

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Number and severity of adverse events post-dose	10 weeks	To count the number and assess the severity of treatment emergent adverse events within 10 weeks post dose

Secondary Outcome Measures

Name	Time	Method
Coagulation (fibrinogen, PT, aPTT)	10 weeks
Anti-drug antibody	16 weeks
D-dimer	10 weeks
alpha2-antiplasmin activity	10 weeks
Pharmacokinetic parameter, maximum concentration of TS23	10 weeks	Pharmacokinetic parameter Cmax of TS23 in plasma
Pharmacokinetic parameter, half-life of TS23	10 weeks	Pharmacokinetic parameter, time required for TS23 concentrations to fall by half